Back to results
US 12,766,201 B2Granted
Urokinase plasminogen activator receptor targeted radiolabeled peptide conjugates
AssigneeCurasight A/S
InventorsAndreas Kjaer, Knud Jorgen Jensen, Jakob Madsen, Troels Elmer Jeppesen
Life of this patent
Estimating the term…
Abstract
The present invention describes Urokinase Plasminogen Activator Receptor (uPAR) targeted radiolabeled conjugates suited for non-invasive PET imaging, SPECT imaging or targeted radionuclide therapy. In particular, but not limited to, the invention related to imaging and therapy of cancer diseases.
Claims33
A urokinase Plasminogen Activator Receptor targeting peptide conjugate comprising:
- a radionuclide coupled via a chelating agent or covalently coupled to a peptide binding to the urokinase Plasminogen Activator Receptor;
- and
- a linker group, wherein the peptide binding to the urokinase Plasminogen Activator Receptor and the linker group is connected by a covalent bond, wherein the linker group comprises an oligo-ethylene glycol, an oligo-glycerol, an oligo-lactic acid, a carbohydrate, an oligo-ethylene glycol connected by a covalent bond to at least one amino acid, an oligo-glycerol connected by a covalent bond to at least one amino acid, an oligo-lactic acid connected by a covalent bond to at least one amino acid, or a carbohydrate connected by a covalent bond to at least one amino acid, and
- wherein the peptide binding to the urokinase Plasminogen Activator Receptor has a sequence chosen from:
- AE344:
- EE-O2Oc-O2Oc-DChaFsrYLWS-OH;
- AE345:
- EE-O2Oc-O2Oc-DChaFsrYLWS-NH2;
- AE346:
- O2Oc-O2Oc-DChaFsrYLWS-OH;
- AE347:
- EE-O2Oc-DChaFsrYLWS-NH2;
- AE348:
- E-O2Oc-DChaFsrYLWS-NH2;
- or
- AE349:
- EE-DChaFsrYLWS-OH.
14 more elements
Dependencies are inferred from the claim text.